First implantable continuous glucose sensor to achieve high accuracy...
SMSI STUDY RESULTS SHOW 96.8% ACCURACY Germantown, Maryland, USA – September 12, 2011 - Sensors for Medicine and Science, Inc. (SMSI) announced today that data from a human pilot study of its...
View ArticleSensors for Medicine and Science Raises $54.1 million Series D Financing
GERMANTOWN, MD. – November 1, 2011 – Sensors for Medicine and Science, Inc. (SMSI), a privately held medical device company focused on the development and commercialization of the first fully...
View ArticleSensors for Medicine and Science Changes Company Name to Senseonics
PIVOTAL STUDY PROTOCOL SUBMITTED TO EUROPEAN REGULATORY BODIES FOR APPROVAL GERMANTOWN, MD. – October 16, 2012 – Sensors for Medicine and Science, Inc., a privately held medical device company focused...
View ArticleSenseonics Receives ISO13485 Certification
GERMANTOWN, MD. – February 20, 2013 – Senseonics, a privately held medical device company focused on the development and commercialization of the first fully implantable, long-term continuous glucose...
View ArticleSenseonics Raises $20 Million; Brings in New VP of Sales and Marketing
GERMANTOWN, MD. – June 5, 2014 – Senseonics, a privately held medical device company focused on the development and commercialization of the first fully implantable, long-term continuous glucose...
View ArticleSenseonics and Rubin Medical to Partner in Scandinavia to Commercialize New...
EXCLUSIVE DISTRIBUTION OF SENSEONICS’ CONTINUOUS GLUCOSE SENSOR IN SWEDEN, NORWAY, AND DENMARK GERMANTOWN, MD. May 5, 2015 – Senseonics, Incorporated, a privately held medical device company focused on...
View ArticleSenseonics Reports CGM Europe Pivotal Study Results
PRIMARY EFFECTIVENESS AND SAFETY ENDPOINTS MET; CE MARK PENDING GERMANTOWN, MD – October 27, 2015 – Senseonics, Incorporated, a privately held medical device company focused on the development and...
View ArticleSenseonics Holdings, Inc. and ASN Technologies, Inc. Announce Closing of Merger
GERMANTOWN, MD–(Marketwired – December 11, 2015) – Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose...
View ArticleSenseonics Announces Start of PRECISE II U.S. Trial of Long-Term CGM
Study of the Eversense® CGM System, a 90-Day Implantable Glucose Sensor GERMANTOWN, MD – January 20, 2016 – Senseonics, Incorporated today announced the start of the PRECISE II (A Prospective,...
View ArticleSenseonics Executes Agreement with Diasend
Companies to Collaborate on Integrated Continuous Glucose Data Management Solution GERMANTOWN, MD – February 2, 2016 – Senseonics Holdings, Inc. (OTCBB: SENH), a medical technology company focused...
View Article
